论文部分内容阅读
目的:探讨黛力新与文拉法辛缓释片对放疗期间宫颈癌患者焦虑抑郁的早期影响。方法:在我院确诊109例宫颈癌合并焦虑、抑郁患者按入院先后时间顺序,随机分为研究组56例与对照组53例,两组在常规治疗基础上分别予黛力新和文拉法辛缓释片行5周治疗观察。采用焦虑自评量表(SAS)、抑郁自评量表(SDS)评定治疗效果。评价不良反应采用副反应量表(TESS)。结果:两组治疗5周后,研究组SAS、SDS评分与治疗前比较下降显著,差异有统计学意义(t=-12.478,-12.457;P<0.01);对照组SAS、SDS评分与治疗前比较下降显著,差异有统计学意义(t=-16.717,-10.622;P<0.01)。两组TESS评分差异无统计学意义(t=-1.555,P=0.123),两组治疗中无明显不良反应出现。结论:黛力新、文拉法辛缓释片早期均具有较好的抗焦虑、抑郁作用,安全性有效,无明显不良反应。
OBJECTIVE: To investigate the early effects of dextromethorphan and venlafaxine extended release tablets on anxiety and depression in patients with cervical cancer during radiotherapy. Methods: 109 cases of cervical cancer with anxiety and depression diagnosed in our hospital were randomly divided into study group (56 cases) and control group (53 cases) according to the sequence of hospital admission. The two groups were treated with dextrose and venlafaxine Sustained release tablets for 5 weeks treatment observation. The anxiety self-rating scale (SAS) and depression self-rating scale (SDS) were used to evaluate the therapeutic effect. Adverse reactions were evaluated using the Side Effects Inventory (TESS). Results: After two weeks of treatment, SAS and SDS scores of the study group decreased significantly compared with those before treatment (t = -12.478, -12.457, P <0.01) The difference was statistically significant (t = -16.717, -10.622; P <0.01). There was no significant difference in TESS scores between the two groups (t = -1.555, P = 0.123). No adverse reactions occurred in the two groups. CONCLUSION: Both Deanxit and venlafaxine sustained-release tablets have better anti-anxiety and depression effects in the early stage and are safe and effective with no obvious adverse reactions.